Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forMississippi

Map
Mississippi
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$19.4 million
to Mississippi research institutions
200+ new jobs
for Mississippi
Mississippi

Neglected diseases in Mississippi

Chikungunya cases
Chikungunya cases
9
Dengue cases
Dengue cases
6
HIV diagnoses
HIV diagnoses
4334
Malaria cases
Malaria cases
18
Tuberculosis cases
Tuberculosis cases
799
West Nile cases
West Nile cases
594
Zika cases
Zika cases
25
Mississippi's top USG-funded global health R&D institutions

Mississippi's top USG-funded global health R&D institutions

University of Mississippi (including University of Mississippi Medical Center)
$18.1 million
University of Southern Mississippi
$724 thousand
Jackson State University
$269 thousand
Mississippi State University
$202 thousand
Mississippi University for Women
$164 thousand
Mississippi industry in global health R&D

Mississippi industry in global health R&D

ElSohly Laboratories
Location(s): Oxford
Emergent Biosolutions
Location(s): Hattiesburg

Mississippi's top areas of global health R&D by USG funding

86.9%
Malaria
4.8%
Hepatitis C
3.4%
Neglected tropical diseases
Dengue
Kinetoplastids
0.9%
Other
HIV/AIDS
Tuberculosis
Global health R&D at work in Mississippi
Global health R&D at work in Mississippi

The University of Mississippi School of Pharmacy is working to make a common malaria drug safer. Primaquine is an inexpensive drug that is highly effective against malaria. However, people with a certain enzyme deficiency can have a life-threatening reaction to the drug. This deficiency is common in regions where malaria is found, so many public health programs are reluctant to use primaquine. If the researchers can alter the drug to stop the reaction, it could be used more widely. Malaria infects more than 200 million people each year, killing almost half a million, most of whom are young children.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Claire Suni
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In